likely critical in chronic allograft rejection. 3 Currently, there are limited means to intervene therapeutically in preventing chronic graft rejection. Hence, there is a practical need in identifying the identity as well as regulators of innate immune cells in triggering chronic damage to the transplanted organs.
In the clinical setting, the intensity of macrophage infiltration in the grafts is correlated with the increased incidence of chronic rejection and poor transplant outcomes. 4, 5 In multiple animal models, macrophages represent a major innate cell type in chronically rejected allografts, 6 and partial depletion of macrophages by a chemical compound carrageenan leads to a 70% reduction in the development of cardiac allograft vasculopathy (CAV), a typical form of chronic rejection of heart transplants.
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These data suggest that macrophages infiltrating the grafts are capable of shaping the alloimmune responses toward chronic rejection. However, certain macrophage subsets in the grafts, such as those expressing the surface markers TIM-4 and DC-SIGN, can also promote allograft acceptance by limiting the allogeneic T cell response or by boosting the frequency of T regulatory cells (Treg). [8] [9] [10] In fact, macrophages are an extremely heterogeneous and dynamic cell type 6, 11 ; they are highly adaptive to environmental cues and constantly adjusting their phenotypes and functions. This issue has been studied in considerable depth in cancer models, but the impact of macrophage subpopulations on transplant outcomes, especially on chronic graft loss, remains poorly defined.
Conceptually, macrophages could develop into functionally diverse subsets, ranging from proinflammatory to antiinflammatory cell types, with M1 and M2 cells representing the extreme ends of a broad spectrum. 12 , 13 The induction of M1 cells requires Toll-like receptor (TLR) stimulation or under conditions of type 1 immunity, 12 those signals converge on nuclear factor-kappa B (NF-κB) activation, which drives M1 cells to express inducible nitric oxide synthase and produce potent inflammatory cytokines.
14 Under M1 cell-polarizing conditions, the tumor necrosis factor receptor-associated factor 6 (TRAF6) acts as a critical adaptor protein in the activation of the NF-kB pathway in M1 cells. 15 On the other hand, M2 polarization depends on IL-4 and IL-13, and these cytokines signal through the Janus kinase/signal transducers and activators of transcription pathway, which usually leads to the activation of mTOR and other downstream signaling events. 16 In fact, pharmacological inhibition of mTOR complex 1 (mTORC1) by rapamycin or specific deletion of mTORC2 in macrophages can markedly reduce IL-4/ IL-13-mediated M2 polarization. 17, 18 Therefore, TRAF6 and mTOR are pivotal signaling molecules in orchestrating M1 and M2 polarization.
We and others have previously reported that macrophages infiltrating the cardiac allografts displayed an M2 phenotype during chronic allograft rejection. 6, 19 Thus understanding the regulatory mechanisms that favor M2 induction in transplant models is an important and clinically relevant issue. In the present study, we generated mouse models in which the TRAF6 and mTOR were selectively deleted in monocytes/ macrophages and used such conditional knockout mice as transplant recipients to examine the role of macrophage subpopulations in chronic allograft rejection. We found that conditional deletion of TRAF6 and mTOR in macrophages differentially affected the induction of M1 and M2 cells. Furthermore, treatment of TRAF6-deleted mice with cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-Ig-induced prominent chronic rejection of heart allografts, whereas treatment of mTOR-deleted mice produced long-term heart allograft survival, free of histological signs of chronic graft rejection. Of interest, graft survival in CTLA4-Ig-treated conditional mTOR-deleted mice was dependent on the PD-1/PD-L1 pathway. These results highlight the importance of the mTOR-M2-PD-L1 regulatory axis in the control of transplant outcomes under costimulatory blockade conditions. Louis, MO). Human recombinant CTLA4-Ig was purchased from BristolMyers-Squibb (New York, NY). Anti-PD-L1 monoclonal antibody (mAb) (10F.9G2) was purchased from BioXCell (West Lebanon, NH).
| MATERIALS AND METHODS

| Mice
| Reagents
| Immunoblotting analysis
Protein extracts from bone marrow-derived macrophages (BMDMs) and T cells were boiled, resolved by sodium dodecyl sulfate polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA), and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes were blocked in Tris-buffered saline containing 0.5% Tween 20 and 5%
bovine serum albumin, washed, and incubated overnight with antibodies in Tris-buffered saline containing 0.5% Tween 20, and then washed and incubated for 1 h with appropriate horseradish peroxidase-coupled secondary antibodies. The specific bands were visualized using the enhanced chemiluminescence reagents (Thermo Scientific, Waltham, MA). For all immunoblotting experiments, β-actin was used as a loading control.
| Quantitative reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA), and reverse-transcription was performed using the complementary DNA synthesis kit (Applied Biosystems, Foster City, CA). The reaction protocol included a 10 minute incubation time at 95°C. The amplification cycles consisted of 95°C for 10 seconds, 60°C for 20 seconds, and 72°C for 20 seconds for each cycle for a total of 40 cycles, followed by a final elongation at 72°C for 5 minutes. All primers used for the studies are listed in Table 1 . Quantitative RT-PCR was performed with a Bio-Rad PCR machine CFX96 (Hercules, CA) using the SYBR Green mix (Bio-Rad).
All data were expressed as the ratio between the expressions of the target gene to HPRT. Fold changes in target gene expression were analyzed by CFX Manager Software (Bio-Rad) using the delta/delta CT method. 
| In vitro M1 and M2 macrophage polarization
| Heterotopic cardiac transplantation
The donor heart grafts were harvested from BALB/c mice and then transplanted into the abdominal cavity of recipient mice by anastomosing the ascending aorta and pulmonary artery of the graft end-to-side to the recipient's abdominal aorta and vena cava as described previously. 19 Graft survival was monitored by daily trans-abdominal palpation, and graft rejection was defined as complete cessation of palpable 
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washed with phosphate buffered saline, and then digested at 37°C 
| Tissue histology and morphometric analysis of graft arteries
The heart grafts were harvested, formalin fixed, and paraffin embedded.
Tissue blocks were sectioned at 5 μm. Slides were baked at 60°C for 
| Statistical analysis
Results are represented as mean ± SEM and analyzed with Prism software (ver. 5.0c, GraphPad). Graft survival was compared using the log-rank test. For ex vivo experiments, the significance of between multiple groups was accessed by analysis of variance with Dunnett's test. Other measurements were performed using unpaired Student's t-test. P < .05 was considered statistically significant.
| RESULTS
| The signaling molecules TRAF6 and mTOR in regulation of M1 and M2 polarization
To generate conditional cell type-specific knockout mice, we crossed 
| Conditional deletion of mTOR or TRAF6 in macrophages does not alter acute allograft rejection
To determine the potential impact of macrophage-specific deletion of TRAF6 and mTOR on allograft rejection, we transplanted the fully MHC-mismatched Balb/c heart allografts into LysM 
| Conditional deletion of mTOR, but not TRAF6, in macrophages inhibits chronic rejection in CTLA4-Ig-treated mice
To further examine whether conditional deletion of TRAF6 and 
| Conditional deletion of mTOR in macrophages expands Foxp3 + Tregs in the allografts
To define the mechanisms by which deletion of mTOR in macrophage promotes long-term allograft survival, we assessed the phenotype of graft-infiltrating cells in CTLA4-Ig-treated mice 14 and 
| Conditional deletion mTOR in recipient mice induces increased PD-L1 expression by graftinfiltrating macrophages
We isolated graft-infiltrating macrophages from CTLA4-Ig-treated Figure 7A ), although the number of graftinfiltrating macrophages was similar among all groups ( Figure 6A) . This 
| DISCUSSION
In the present study we generated conditional knockout mice in which TRAF6 and mTOR were selectively deleted in macrophages and macrophages then contribute to acute rejection by producing proinflammatory cytokines, such as IL-1β, IL-6, IL-12, and tumor-necrosis factor α (TNF-α), which are abundantly expressed in graft biopsies during acute allograft rejection. 25, 26 However, acute allograft rejection is primarily a T cell-mediated event, and the robust T cell activation is necessary and sufficient in mediating acute graft loss.
Thus suppression of M1 cells alone, as we show in this study using TRAF6-deleted mice, provides little effects in setting of acute allograft rejection. Our data are consistent with earlier observations that targeting T cell activation is a prerequisite in preventing acute allograft rejection.
Data from clinical and preclinical studies repeatedly demonstrate that inhibition of T cell responses, especially the type 1 T cell immunity, often failed to ensure long-term graft acceptance. 27 In fact, graft loss in the presence of broad immunosuppression therapies is mostly associated with the development of chronic allograft rejection, a complex process that involves a multiplicity of cell types. 6, 28, 29 In animal models, we and others have highlighted the significance of M2 macrophages in chronic graft loss. 6, 19 In kidney and heart transplantation in the clinic, there is a strong correlation between graft-infiltrating M2 cells and signs of interstitial fibrosis, suggesting that M2 macrophages have the potential to promote development of interstitial fibrosis. 5, 30, 31 Mechanistically, M2 cells can produce growth factors such as transforming growth factor-β and platelet-derived growth factor, which are crucial mediators of vascular changes, by inducing smooth muscle cell proliferation, activation of myofibroblasts, and extracellular matrix deposition. 32, 33 Moreover, a recent report indicates that α-smooth muscle actin positive myofibroblasts contribute to interstitial fibrosis in chronic renal allograft injury, and that approximately 50% of these myofibroblasts are derived from M2 macrophages. 34 All these studies suggest the significance of M2 macrophages in mediating chronic allograft rejection. In the present study we found that mTOR deletion In certain transplant models, the mTOR inhibitor rapamycin has been shown to inhibit neointimal formation and chronic graft rejection, 17, 35, 36 and our data argue for the importance of M2 suppression by rapamycin, in addition to its effects on T cells, in chronic rejection.
However, mechanisms of acute and chronic rejection are so different, in that some form of immunosuppression therapies to inhibit It is notable that inhibition of mTORC2 has been shown to upregulate PD-L1 expression on dendritic cells, as well as on a human lung carcinoma cell line. 38, 39 Given these findings, it is possible that in polarizing macrophages, mTOR activation inhibits PD-L1 expression, and its absence or inhibition favors PD-L1 expression by macrophages. This notion warrants further investigation in future studies.
In summary, conditional deletion of mTOR in macrophages exhibits profound effects on graft survival under conditions of costimulatory blockade. We provide data that mTOR deletion suppress M2 polarization and inhibit chronic allograft rejection. Moreover, mTOR deleted macrophages overexpress PD-L1 and exert potent immune regulatory function in mediating long-term graft survival. Our data demonstrate that the potential impact of macrophage subpopulations on chronic rejection versus graft acceptance is significant, especially in the presence of costimulatory blockade treatment.
